Resource Summary Report

Generated by dkNET on Aug 17, 2026

Biogen Idec

RRID:SCR_003790
Type: Tool

Proper Citation

Biogen Idec (RRID:SCR_003790)

Resource Information

URL: https://www.biogen.com/en_us/home.html

Proper Citation: Biogen Idec (RRID:SCR_003790)

Description: Global biotechnology company based in Cambridge, Massachusetts, specializing in discovering, developing, and delivering important therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases to patients worldwide.

Abbreviations: BIIB

Synonyms: Biogen Idec Inc.

Resource Type: commercial organization

Keywords: drug, biotechnology

Related Condition: Neurodegenerative disease, Hematologic disease, Autoimmune disease, Multiple Sclerosis, Hemophilia

Resource Name: Biogen Idec

Resource ID: SCR_003790

Alternate IDs: nlx_158083

Old URLs: http://www.biogenidec.com/

Record Creation Time: 20220129T080220+0000

Record Last Update: 20260815T182235+0000

Ratings and Alerts

No rating or validation information has been found for Biogen Idec.

No alerts have been found for Biogen Idec.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 564 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Yang W, et al. (2025) From Lab to Clinic: Effect of Academia-Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry. Clinical and translational science, 18(1), e70135.

Lovett A, et al. (2025) Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis. Muscle & nerve, 71(6), 1006.

Grillo P, et al. (2025) Amplification parameters of the alpha-synuclein seed amplification assay on CSF predict the clinical subtype of Parkinson's Disease at 10-year follow-up. medRxiv : the preprint server for health sciences.

Phadke RA, et al. (2025) The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking. Molecular psychiatry, 30(2), 796.

Yousuf MS, et al. (2025) Diroximel Fumarate Acts Through Nrf2 to Attenuate Methylglyoxal-Induced Nociception in Mice and Decrease ISR Activation in DRG Neurons. Diabetes, 74(5), 827.

Chaves B, et al. (2025) In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis. Nature communications, 16(1), 5533.

Jiang D, et al. (2025) Quantitative Determination of Click-Reactive Antisense Oligonucleotide and Its Reactivity in Rat Brains by Hybridization LC-MS/MS to Support Pretargeted PET Imaging. Analytical chemistry, 97(23), 12155.

Lynch JP, et al. (2025) Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis. mAbs, 17(1), 2505090.

de Sèze J, et al. (2025) LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France. Advances in therapy, 42(4), 1760.

Van Zyl M, et al. (2025) Brain-Death in Rats Increases Neutrophil Extracellular Trap Formation in Donor Organs. Transplant international : official journal of the European Society for Organ Transplantation, 38, 14223.

Butler PM, et al. (2025) Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment. Nature medicine, 31(3), 829.

Sato K, et al. (2025) Sentiment analysis of social media responses to the approval of lecanemab for the treatment of Alzheimer's disease in Japan. Journal of Alzheimer's disease reports, 9, 25424823241307639.

Bast N, et al. (2025) Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry. The Lancet regional health. Europe, 48, 101137.

Filippi M, et al. (2025) Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project. Journal of neurology, 272(1), 96.

Droby A, et al. (2025) Radiological markers of CSF ?-synuclein aggregation in Parkinson's disease patients. NPJ Parkinson's disease, 11(1), 7.

Dagunts A, et al. (2024) Retromer Opposes Opioid-Induced Downregulation of the Mu Opioid Receptor. bioRxiv : the preprint server for biology.

Jiang D, et al. (2024) Bioanalysis of free antisense oligonucleotide payload from antibody-oligonucleotide conjugate by hybridization LC-MS/MS. Bioanalysis, 16(15), 791.

Foley JF, et al. (2024) Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis. Neurology(R) neuroimmunology & neuroinflammation, 11(6), e200321.

Sun C, et al. (2024) Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction. Hepatology communications, 8(11).

Wu Y, et al. (2024) Chlamydia-driven ISG15 expression dampens the immune response of epithelial cells independently of ISGylation. mBio, 15(11), e0240124.